Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Ann Surg Oncol. 2010 Feb;17(2):624-33. doi: 10.1245/s10434-009-0831-8.
In 2008, the National Comprehensive Cancer Network suggested conducting a KRAS mutations test in metastatic colorectal cancer (mCRC) patients prior to administering therapy that uses anti-epidermal growth factor receptor (EGFR) monoclonal antibody. However, tests of KRAS mutations have been limited when traditional molecular techniques, such as polymerase chain reaction (PCR) combined direct sequencing, are used to obtain and analyze patients' cancer tissues. If the primary tumor or metastatic tissues of patients with mCRC is unavailable, then such analysis will not be feasible. Our laboratory has successfully established a colorimetric membrane array analysis platform that could detect activating KRAS mutations from the peripheral blood of patients with various malignancies.
The current research aims to improve the above-mentioned technique not only by using chemiluminescence detection to replace color development, but also to add scores weighted according to the relevance of each gene to activating KRAS mutations.
Our results show that the described weighted chemiluminescent membrane array (WCHMA) can detect circulating tumor cells (CTCs) harboring activating KRAS mutations in the peripheral blood in CRC. The sensitivity, specificity, and accuracy were 90.2, 94.9, and 93.5%, respectively, and the detection limitation was three colon tumor cells per millimeter of blood. The current study would significantly improve the detection sensitivity and accuracy over that of our previously designed membrane array method.
These findings also highlight the need to prompt further prospective studies on more cases of CRC to further establish the clinical relevance of activating KRAS mutation detection from peripheral blood in anti- EGFR-based chemotherapy that uses activating KRAS detection chips and the WCHMA analysis method.
2008 年,美国国家综合癌症网络建议在转移性结直肠癌(mCRC)患者接受抗表皮生长因子受体(EGFR)单克隆抗体治疗前进行 KRAS 基因突变检测。然而,当使用聚合酶链反应(PCR)结合直接测序等传统分子技术获取和分析患者的肿瘤组织时,KRAS 基因突变检测受到限制。如果 mCRC 患者的原发肿瘤或转移组织不可用,则无法进行此类分析。我们的实验室已经成功建立了一种比色膜阵列分析平台,能够从各种恶性肿瘤患者的外周血中检测到激活的 KRAS 突变。
本研究旨在不仅使用化学发光检测代替显色,而且根据每个基因与激活的 KRAS 突变的相关性添加加权分数,来改进上述技术。
我们的结果表明,所描述的加权化学发光膜阵列(WCHMA)可以检测到 CRC 患者外周血中携带激活的 KRAS 突变的循环肿瘤细胞(CTC)。敏感性、特异性和准确性分别为 90.2%、94.9%和 93.5%,检测限为每毫米血液 3 个结肠肿瘤细胞。与我们之前设计的膜阵列方法相比,本研究显著提高了检测的敏感性和准确性。
这些发现还强调需要进一步前瞻性研究更多 CRC 病例,以进一步确定基于抗 EGFR 的化疗中使用激活的 KRAS 检测芯片和 WCHMA 分析方法从外周血中检测激活的 KRAS 突变的临床相关性。